Based on this, some bioactive materials can be used to improve the bone integration capacity of the porous PEEK, such as bone morphogenetic protein 2 [9], osteogenic growth peptide [10], albumin [11], etc. As an active sequence associated with bone remodeling, human parathyroid hormone (PTH) (1-34) has received approval from the US Food and Drug Administration for clinical use in treating bone defects and osteoporosis [12]. This evidence concerns the gene PTH and osteoporosis.